Terns Pharmaceuticals, Inc. [Rocket]

In millions, except per share items	Jun-30-23	Jun-05-23	Mar-31-23	Mar-05-23	Dec-31-22	Dec-05-22	Sep-30-22	Sep-05-22
	10-Q	8-K	10-Q	8-K	10-K	8-K	10-Q	8-K
Total revenues	17.1		10.7		12.2		9.7
Revenue growth	1605.6%		965.8%		1116.1%
Cost of goods sold	55.5		22.0		33.5		33.3
Gross profit	-21.4		-11.3		-21.4		-18.3
Gross margin	-225.3%		-106.0%		-175.8%		-245.1%
Selling, general and administrative [+]	22.2		30.9		19.2		16.1
General and administrative	36.5		34.9		38.7
Other selling, general and administrative					-14.4
Research and development	43.4		37.9				29.0
Other operating expenses					10.9		-0.6
EBITDA [+]	-78.8		-71.7		-60.9		-59.0
EBITDA growth	48.6%		45.4%		24.1%		33.4%
EBITDA margin	-462.5%		-680.6%		-500.6%		-611.6%
Depreciation and amortization	0.4		0.4		0.5		0.5
EBIT [+]	-79.2		-72.1		-61.2		-59.5
EBIT growth	47.7%		44.6%		24.0%		32.7%
EBIT margin	-464.1%		-683.6%		-503.6%		-615.4%
Interest income	5.2		4.7		1.6		0.8
Interest income	7.9		4.7		2.1		0.8
Other income (expense), net [+]	2.3		0.4		-0.4		0.3
Other	-0.1		-0.1		-0.1
Pre-tax income	-71.6		-67.7		-60.0		-58.3
Income taxes	0.5		0.4		0.4		0.5
Net income	-95.1		-68.1		-104.9		-94.7
Net margin	-557.3%		-639.0%		-862.3%		-979.9%

Basic EPS [+]	($0.01)		($1.45)		($3.35)		($3.39)
Growth	-29.9%		32.3%		-14.2%		58.4%
Diluted EPS [+]	($0.01)		($1.45)		($3.35)		($3.39)
Growth	-29.9%		32.3%		-14.2%		58.4%

Shares outstanding (basic) [+]	17,481.1		47.1		31.3		27.9
Growth	70941.2%		91.7%		42.0%		70.1%
Shares outstanding (diluted) [+]	17,481.1		47.1		31.3		27.9
Growth	70941.2%		91.7%		42.0%		70.1%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.